Total Payments
$442,672
2024 Payments
$36,129
Companies
22
Transactions
476
Medicare Patients
5,560
Medicare Billing
$1.5M
Payment Breakdown by Category
Other$302,354 (68.3%)
Consulting$99,760 (22.5%)
Travel$31,985 (7.2%)
Food & Beverage$8,071 (1.8%)
Research$290.57 (0.1%)
Education$211.44 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $299,893 | 141 | 67.7% |
| Consulting Fee | $99,760 | 52 | 22.5% |
| Travel and Lodging | $31,985 | 99 | 7.2% |
| Food and Beverage | $8,071 | 173 | 1.8% |
| Honoraria | $2,350 | 3 | 0.5% |
| Unspecified | $290.57 | 4 | 0.1% |
| Education | $211.44 | 3 | 0.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $111.11 | 1 | 0.0% |
Payments by Type
General
$442,381
472 transactions
Research
$290.57
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $110,625 | 132 | $0 (2023) |
| Celgene Corporation | $85,981 | 94 | $0 (2024) |
| Janssen Biotech, Inc. | $54,035 | 71 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $49,827 | 41 | $0 (2021) |
| GENZYME CORPORATION | $31,554 | 18 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $31,267 | 22 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $25,934 | 18 | $0 (2017) |
| PFIZER INC. | $23,102 | 12 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $14,398 | 21 | $0 (2023) |
| Janssen Global Services, LLC | $4,434 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $36,129 | 33 | Janssen Biotech, Inc. ($14,523) |
| 2023 | $28,770 | 31 | Janssen Biotech, Inc. ($7,580) |
| 2022 | $22,802 | 30 | GENZYME CORPORATION ($6,593) |
| 2021 | $31,704 | 37 | Celgene Corporation ($17,846) |
| 2020 | $26,185 | 20 | Janssen Biotech, Inc. ($9,695) |
| 2019 | $57,031 | 62 | Janssen Biotech, Inc. ($15,033) |
| 2018 | $127,798 | 126 | Amgen Inc. ($55,452) |
| 2017 | $112,254 | 137 | Celgene Corporation ($42,259) |
All Payment Transactions
476 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,570.00 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | Legend Biotech USA Inc. | — | Consulting Fee | Cash or cash equivalent | $2,955.00 | General |
| 12/12/2024 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $27.28 | General |
| 12/08/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $83.04 | General |
| Category: Oncology | ||||||
| 12/08/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $69.57 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $61.69 | General |
| 12/06/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $24.98 | General |
| 11/29/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | Cash or cash equivalent | $60.00 | General |
| Category: Oncology | ||||||
| 11/29/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | Cash or cash equivalent | $20.10 | General |
| Category: Oncology | ||||||
| 11/29/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | Cash or cash equivalent | $17.00 | General |
| Category: Oncology | ||||||
| 11/29/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | Cash or cash equivalent | $6.53 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,575.00 | General |
| Category: Oncology | ||||||
| 10/31/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: ONCOLOGY | ||||||
| 09/27/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug), XPOVIO | Consulting Fee | Cash or cash equivalent | $2,037.50 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug), XPOVIO | Food and Beverage | In-kind items and services | $243.16 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug), XPOVIO | Travel and Lodging | Cash or cash equivalent | $10.33 | General |
| Category: Oncology | ||||||
| 08/28/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 08/21/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $187.19 | General |
| Category: Hematology | ||||||
| 07/31/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Consulting Fee | Cash or cash equivalent | $1,575.00 | General |
| Category: Oncology | ||||||
| 07/31/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Travel and Lodging | Cash or cash equivalent | $10.48 | General |
| Category: Oncology | ||||||
| 07/31/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Travel and Lodging | Cash or cash equivalent | $8.19 | General |
| Category: Oncology | ||||||
| 06/27/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Food and Beverage | In-kind items and services | $89.96 | General |
| Category: Oncology | ||||||
| 06/04/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE II, OPEN LABEL, RANDOMIZED, TWO-ARM STUDY TO INVESTIGATE THE E | GlaxoSmithKline, LLC. | $290.57 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 981 | 4,437 | $814,122 | $283,524 |
| 2022 | 17 | 1,323 | 3,873 | $710,599 | $268,588 |
| 2021 | 16 | 1,635 | 6,523 | $889,855 | $371,219 |
| 2020 | 16 | 1,621 | 9,224 | $1.5M | $620,053 |
Total Patients
5,560
Total Services
24,057
Medicare Billing
$1.5M
Procedure Codes
63
All Medicare Procedures & Services
63 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 405 | 1,135 | $341,140 | $167,385 | 49.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 46 | 249 | $54,984 | $23,800 | 43.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 105 | 186 | $44,244 | $19,025 | 43.0% |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 2023 | 11 | 156 | $135,828 | $16,844 | 12.4% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 24 | 2,100 | $90,300 | $12,364 | 13.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 61 | 73 | $30,778 | $10,376 | 33.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 51 | 51 | $23,308 | $9,427 | 40.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 37 | 90 | $13,899 | $6,088 | 43.8% |
| 38221 | Biopsy of bone marrow | Office | 2023 | 38 | 38 | $23,699 | $5,563 | 23.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 71 | 186 | $11,048 | $5,118 | 46.3% |
| 38220 | Aspiration of bone marrow sample for diagnosis | Office | 2023 | 38 | 38 | $21,937 | $2,690 | 12.3% |
| 85097 | Bone marrow, smear interpretation | Office | 2023 | 40 | 41 | $13,275 | $2,413 | 18.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 20 | 25 | $4,297 | $1,600 | 37.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 34 | 69 | $5,385 | $831.60 | 15.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 390 | 1,031 | $309,300 | $148,927 | 48.1% |
| Q5111 | Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg | Office | 2022 | 18 | 228 | $154,872 | $31,041 | 20.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 122 | 200 | $50,000 | $21,773 | 43.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 47 | 168 | $33,600 | $14,595 | 43.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 48 | 48 | $23,520 | $9,221 | 39.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 47 | 54 | $23,220 | $8,586 | 37.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 350 | 897 | $26,910 | $6,666 | 24.8% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2022 | 11 | 800 | $16,000 | $5,193 | 32.5% |
| 38221 | Biopsy of bone marrow | Office | 2022 | 34 | 35 | $18,375 | $5,036 | 27.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 63 | 150 | $7,500 | $4,268 | 56.9% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 11 | 21 | $3,360 | $3,357 | 99.9% |
About Dr. Noa Biran, M.D
Dr. Noa Biran, M.D is a Hematology healthcare provider based in Hackensack, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/05/2008. The National Provider Identifier (NPI) number assigned to this provider is 1023277910.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Noa Biran, M.D has received a total of $442,672 in payments from pharmaceutical and medical device companies, with $36,129 received in 2024. These payments were reported across 476 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($299,893).
As a Medicare-enrolled provider, Biran has provided services to 5,560 Medicare beneficiaries, totaling 24,057 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 63 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location Hackensack, NJ
- Active Since 06/05/2008
- Last Updated 01/26/2022
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1023277910
Products in Payments
- NINLARO (Drug) $75,761
- Revlimid (Drug) $66,351
- Kyprolis (Biological) $65,192
- DARZALEX (Biological) $63,884
- XGEVA (Biological) $26,655
- SARCLISA (Biological) $17,783
- ELREXFIO (Drug) $14,988
- ABECMA (Biological) $12,211
- DARZALEX (Drug) $9,238
- TECVAYLI (Biological) $8,403
- EMPLICITI (Biological) $8,267
- MOZOBIL (Drug) $4,752
- CD38 (Drug) $3,703
- VENCLEXTA (Drug) $2,600
- XPOVIO (Drug) $2,418
- Pomalyst (Drug) $1,784
- TALVEY (Biological) $1,684
- Cellsearch (Device) $600.00
- Kyprolis (Drug) $500.00
- clonoSEQ (Device) $299.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Hackensack
Dr. James Mccloskey, M.d, M.D
Hematology — Payments: $2.8M
Hematology $2.8M
Dr. Jamie Koprivnikar, M.d, M.D
Hematology — Payments: $1.5M
Hematology $1.5M
Dr. Andrew Pecora, Md, MD
Hematology — Payments: $1.4M
Hematology $1.4M
Dr. David Vesole, Md, MD
Hematology — Payments: $1.1M
Hematology $1.1M
Dr. Lori Leslie, M.d, M.D
Hematology — Payments: $669,511
Hematology $669,511
Dr. Robert Alter, Md, MD
Hematology — Payments: $539,884
Hematology $539,884